DK0679094T3 - Forbindelser til målretning - Google Patents
Forbindelser til målretningInfo
- Publication number
- DK0679094T3 DK0679094T3 DK94904270T DK94904270T DK0679094T3 DK 0679094 T3 DK0679094 T3 DK 0679094T3 DK 94904270 T DK94904270 T DK 94904270T DK 94904270 T DK94904270 T DK 94904270T DK 0679094 T3 DK0679094 T3 DK 0679094T3
- Authority
- DK
- Denmark
- Prior art keywords
- target cell
- image
- compound
- specific
- targeting
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 231100000433 cytotoxic Toxicity 0.000 abstract 3
- 230000001472 cytotoxic effect Effects 0.000 abstract 3
- 102000006382 Ribonucleases Human genes 0.000 abstract 1
- 108010083644 Ribonucleases Proteins 0.000 abstract 1
- 108010090804 Streptavidin Proteins 0.000 abstract 1
- 230000004520 agglutination Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000035931 haemagglutination Effects 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Inorganic Insulating Materials (AREA)
- Glass Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939300686A GB9300686D0 (en) | 1993-01-15 | 1993-01-15 | Compounds for targeting |
PCT/GB1994/000087 WO1994015644A1 (en) | 1993-01-15 | 1994-01-17 | Compounds for targeting |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0679094T3 true DK0679094T3 (da) | 1998-10-19 |
Family
ID=10728728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK94904270T DK0679094T3 (da) | 1993-01-15 | 1994-01-17 | Forbindelser til målretning |
Country Status (10)
Country | Link |
---|---|
US (1) | US5973116A (da) |
EP (2) | EP0679094B1 (da) |
JP (1) | JPH08509460A (da) |
AT (1) | ATE164314T1 (da) |
DE (1) | DE69409225T2 (da) |
DK (1) | DK0679094T3 (da) |
ES (1) | ES2115927T3 (da) |
GB (1) | GB9300686D0 (da) |
GR (1) | GR3026449T3 (da) |
WO (1) | WO1994015644A1 (da) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
CA2200434A1 (en) * | 1994-09-19 | 1996-03-28 | Jacob Bakker | Gene constructs encoding crop-protecting agents, as well as transformed plants containing and expressing such constructs, and methods of controlling plague organisms and pathogensin crops |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US6497881B1 (en) * | 1995-11-30 | 2002-12-24 | New York University | High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein |
US6451995B1 (en) * | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
JPH09324000A (ja) * | 1996-06-05 | 1997-12-16 | Suntory Ltd | インターロイキン−2受容体を特異的に認識する因子とリボヌクレアーゼとの接合体 |
AU4070499A (en) | 1998-04-30 | 1999-11-16 | Cornell Research Foundation Inc. | Adenoviral vectors with tandem fiber proteins |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
WO2000015823A1 (en) | 1998-09-11 | 2000-03-23 | Genvec, Inc. | Alternatively targeted adenovirus |
GB2348203B (en) | 1998-11-04 | 2002-06-19 | Imp College Innovations Ltd | Solube beta-forms of prion proteins, methods of preparation and use |
US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
MXPA01010896A (es) | 1999-04-28 | 2003-06-24 | Genencor Int | Antagonistas cataliticos especificamente dirigidos al objetivo y usos de los mismos. |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
GB9926875D0 (en) * | 1999-11-12 | 2000-01-12 | Microbiological Research Agenc | Use of lytic toxins and toxin conjugates |
AU4430701A (en) * | 2000-04-03 | 2001-10-15 | Antisoma Research Limited | Compounds for targeting |
US7235233B2 (en) | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
US7230085B2 (en) * | 2001-11-28 | 2007-06-12 | Immunomedics, Inc. | Anti-DOTA antibody |
ES2335657T3 (es) | 2002-04-25 | 2010-03-31 | Crucell Holland B.V. | Medios y metodos para la produccion de vectores de adenovirus. |
US7067298B2 (en) * | 2003-03-31 | 2006-06-27 | Ambion, Inc. | Compositions and methods of using a synthetic Dnase I |
WO2008054471A2 (en) * | 2006-03-09 | 2008-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Monolayer-protected gold clusters: improved synthesis and bioconjugation |
KR102378465B1 (ko) | 2009-11-02 | 2022-03-28 | 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 | 치료학적 뉴클레아제 조성물 및 방법 |
KR102161657B1 (ko) | 2011-04-29 | 2020-10-06 | 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 | 치료적 뉴클레아제 조성물 및 방법 |
ES2759252T3 (es) | 2013-10-31 | 2020-05-08 | Resolve Therapeutics Llc | Fusiones y métodos terapéuticos de nucleasa-albúmina |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2550944B1 (fr) * | 1983-08-23 | 1985-12-06 | Sanofi Sa | Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers |
US4863713A (en) * | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
FR2604092B1 (fr) * | 1986-09-19 | 1990-04-13 | Immunotech Sa | Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo |
GB8723661D0 (en) * | 1987-10-08 | 1987-11-11 | British Bio Technology | Synthetic gene |
GB9001641D0 (en) * | 1990-01-24 | 1990-03-21 | Imp Cancer Res Tech | Compounds |
GB9021671D0 (en) * | 1990-10-05 | 1990-11-21 | Unilever Plc | Delivery of agents |
AU7583891A (en) * | 1990-04-17 | 1991-11-11 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Selective cytotoxic reagents comprising toxic moieties derived from mammalian proteins |
IT1245748B (it) * | 1990-12-21 | 1994-10-14 | Mini Ricerca Scient Tecnolog | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego |
US5364612A (en) * | 1991-05-06 | 1994-11-15 | Immunomedics, Inc. | Detection of cardiovascular lesions |
EP1306095A3 (en) * | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
-
1993
- 1993-01-15 GB GB939300686A patent/GB9300686D0/en active Pending
-
1994
- 1994-01-17 DE DE69409225T patent/DE69409225T2/de not_active Expired - Fee Related
- 1994-01-17 EP EP94904270A patent/EP0679094B1/en not_active Expired - Lifetime
- 1994-01-17 AT AT94904270T patent/ATE164314T1/de not_active IP Right Cessation
- 1994-01-17 ES ES94904270T patent/ES2115927T3/es not_active Expired - Lifetime
- 1994-01-17 US US08/491,988 patent/US5973116A/en not_active Expired - Fee Related
- 1994-01-17 WO PCT/GB1994/000087 patent/WO1994015644A1/en active IP Right Grant
- 1994-01-17 JP JP6515851A patent/JPH08509460A/ja not_active Ceased
- 1994-01-17 DK DK94904270T patent/DK0679094T3/da active
- 1994-01-17 EP EP97201981A patent/EP0815872A3/en not_active Withdrawn
-
1998
- 1998-03-26 GR GR980400451T patent/GR3026449T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
GB9300686D0 (en) | 1993-03-03 |
JPH08509460A (ja) | 1996-10-08 |
DE69409225D1 (de) | 1998-04-30 |
US5973116A (en) | 1999-10-26 |
GR3026449T3 (en) | 1998-06-30 |
EP0679094A1 (en) | 1995-11-02 |
ES2115927T3 (es) | 1998-07-01 |
ATE164314T1 (de) | 1998-04-15 |
EP0815872A2 (en) | 1998-01-07 |
EP0815872A3 (en) | 2003-12-10 |
DE69409225T2 (de) | 1998-08-13 |
EP0679094B1 (en) | 1998-03-25 |
WO1994015644A1 (en) | 1994-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0679094T3 (da) | Forbindelser til målretning | |
DE69939820D1 (de) | Internalisierende erbb2 antikörper | |
CY1110556T1 (el) | Ανοσοθεραπεια των αυτοανοσων διαταραχων χρησιμοποιωντας αντισωματα τα οποια στοχευουν τα β-κυτταρα | |
CY1108799T1 (el) | Αντισωμα αντι- ccr5 | |
NO20030621D0 (no) | Anti-dual integrin antistoffer, sammensetninger, fremgangsmåter og anvendelser | |
EP1789447A4 (en) | METHOD OF DELIVERING RNA INTERFERENCE AND USE THEREOF | |
ATE280228T1 (de) | Monoklonaler antikörper gegen rhesus d (d7c2) | |
MY104946A (en) | Antigen antibody conjugate. | |
WO1994019466A3 (en) | A novel family of anti-carcinoembryonic antigen chimeric antibodies | |
CY1106387T1 (el) | Τμηματοποιημενα μορια μεταφορεα αντιγονου (ματ-μορια) για τη διαμορφωση ανοσοαποκρισεων, αντιστοιχα δομηματα, μεθοδοι και χρησεις | |
AU570963B2 (en) | Indole-dihydro-indole alkaloids conjugated with antibodies | |
EP1111385A3 (en) | Enzyme-protein complex | |
GB2289679A (en) | Compounds for targeting | |
WO2003045429A3 (en) | Anti-t cell immunotoxin fusion protein and its therapeutic use | |
DE69935864D1 (de) | Bor-neutronenfangtherapie unter verwendung von pre-targeting-methoden | |
EP0781846A3 (en) | Treponema pallidum fused antigen and assay for anti-treponema pallidum antibodies using the same fused antigen | |
DE3851221T2 (de) | Nichttrennender festphasen-enzymtest. | |
WO2002050120A3 (en) | High affinity antibodies | |
AU1997897A (en) | Nucleic acid-bound polypeptide, method of producing nucleic acid-bound polypeptide, and immunoassay using the polypeptide | |
BR0303226A (pt) | Proteìnas de aderência e penetração de haemophilus | |
NZ314010A (en) | A method of targeting intracellular binding proteins using a lipidized antibody | |
NO923627L (no) | Setespesifikk kutting av enkeltkjedet dna |